September 2012 Issue of MMM
SEPTEMBER 2012 issue
Apple's tablet device, it seems, is now pharma's best friend, too. But it's not as simple as just rolling up to the physician's office, flashing ...
Sites like Novo Nordisk's Cornerstones4Care are bringing full-spectrum segmentation to the task of bolstering adherence and being there for the patient
Ad spend for medical/surgical journals declined by 16.5%, as patent expiries and regulatory delays stifled 2011's comeback bid. Marc Iskowitz reports on the numbers for ...
Though healthcare intelligence firm WorldOne is 12 years old, co-founder and CEO Peter Kirk feels like the company is "just getting started."
Personalized medicines that use companion diagnostics to identify a patient sub-population are the theme of this year's crop of cancer drug approvals.
These steps can equip sales teams to work around limited access, bring value to oncologists and increase sales
The PSA test is a large part of the reason that death from prostate cancer has declined
Pink slips and a restructuring plan that includes shutting its New Jersey manufacturing plant are just the beginning of the coming changes Dendreon.
Shire announced that it was rebranding its Advanced BioHealing unit Shire Regenerative Medicine
News on Novartis, Johnson & Johnson and GlaxoSmithKline
Med Ed Report
The drug industry dialed back its continuing medical education (CME) grant-giving in 2011, continuing a negative trend
A citizens' petition could regulate the way drugmakers market such pain medication as Oxycontin and Percocet
A new video-based educational series will aim to tailor content to both patients and physicians, the firms behind the effort say.
News on the Alliance for Continuing Education in the Health Professions, Med-IQ, AAFP, AMA and EthosCE
The medical journal publisher says advertisers are following the move toward the iPad
Nine Journal of the American Medical Associaiton publications will get new names in 2013
News on Elsevier, Springer and The International Journal of Angiology
Can an article's reprint potential create a publication bias?
Softer revenues led to a double-digit revenue decline for WebMD in the first half, while Everyday Health grew 35% when compared to the first six ...
Remedy Health Media agreed to integrate content from health video provider HealthiNation.
News on Withings, AstraZeneca, Janssen and Topin
Stryker's TV ads for its Get Around Knee seem to be fueling in a spike in consumer interest on the company's website
Merck's terrific new integrated campaign for their shingles vaccine Zostavax
Pfizer is scooping up worldwide marketing rights to the non-prescription version of Nexium for $250 million up front.
The lives of five patients with mutiple sclerosis will be chronicled online as part of a program developed by the National MS Society and Sanofi's ...
In a survey of non-MD health professionals, 55% said they rely primarily on paper-based communications when talking with patients.
News on Pfizer, Oral Cancer Foundation, GlaxoSmithKline and Johnson & Johnson
IMS Health acquired TTC, a Philadelphia-based trial benchmarking and analytics firm
CarbonSix said it launched a tool that can deliver "in the moment" insight about patients living with chronic medical conditions.
Dudnyk bought San Francisco-based Stratagem Healthcare Communications
Astellas tapped independent agency Roska Healthcare as consumer agency-of-record for Astellas' new overactive bladder pill, Myrbetriq
News on JeffreyGroup, Core Nation, Johnson & Johnson, Burson-Marsteller and HCB Health
Companies who submit proprietary data to FDA have a right to ensure it isn't disclosed to competitors
FDA challenged a House report that said its regulations and enforcement actions contribute to drug shortages.
An appeals court ruling says "any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market" can ...
Drug choices will likely narrow to only those therapies with the best clinical and cost efficiency data
Does big spending by the industry on TV ads translate into outstanding creative? Not always.
At Work With
Greg Marta, Director of Digital Marketing, DMW Direct
Bob Harrell, VP of Marketing, Appature
Name That Brand
Brand X shows off its softer side
As with "one-size-fits-all" marketing, the "content-only-driven" strategy is outdated
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.